MA50247B1 - Compositions aqueuses comprenant de la bilastine et du mométasone - Google Patents

Compositions aqueuses comprenant de la bilastine et du mométasone

Info

Publication number
MA50247B1
MA50247B1 MA50247A MA50247A MA50247B1 MA 50247 B1 MA50247 B1 MA 50247B1 MA 50247 A MA50247 A MA 50247A MA 50247 A MA50247 A MA 50247A MA 50247 B1 MA50247 B1 MA 50247B1
Authority
MA
Morocco
Prior art keywords
bilastine
mometasone
pharmaceutical composition
relates
aqueous pharmaceutical
Prior art date
Application number
MA50247A
Other languages
English (en)
Other versions
MA50247A (fr
Inventor
Herrero Gonzalo Hernández
Domínguez Neftalí García
Gorostiza Ana Gonzalo
Arce Arturo Zazpe
Poladura Pablo Morán
García Tania González
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MA50247A publication Critical patent/MA50247A/fr
Publication of MA50247B1 publication Critical patent/MA50247B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique aqueuse comprenant : a) de la bilastine ou un sel ou solvate pharmaceutiquement acceptable de celle-ci, b) du mométasone, ou un dérivé pharmaceutiquement acceptable de celui-ci, c) un agent de suspension, et d) 2-hydroxypropyl-3-cyclodextrine; le ph de la composition pharmaceutique aqueuse étant compris entre 3,5 et 5,5, et la teneur en 2-hydroxypropyl-ß-cyclodextrine étant inférieure à 8,5 % en poids. L'invention concerne également lesdites compositions destinées à être utilisées dans le traitement et/ou la prévention d'un trouble ou d'une maladie susceptible d'améliorer par antagonisme du récepteur de l'histamine h1 et/ou d'une maladie sensible aux corticostéroïdes par administration nasale. L'invention concerne également un procédé de préparation de la composition pharmaceutique aqueuse susmentionnée.
MA50247A 2017-10-16 2018-10-15 Compositions aqueuses comprenant de la bilastine et du mométasone MA50247B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382686 2017-10-16
PCT/EP2018/078034 WO2019076798A1 (fr) 2017-10-16 2018-10-15 Compositions aqueuses comprenant de la bilastine et du mométasone

Publications (2)

Publication Number Publication Date
MA50247A MA50247A (fr) 2020-07-22
MA50247B1 true MA50247B1 (fr) 2021-02-26

Family

ID=60262869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50247A MA50247B1 (fr) 2017-10-16 2018-10-15 Compositions aqueuses comprenant de la bilastine et du mométasone

Country Status (23)

Country Link
US (1) US11642309B2 (fr)
EP (1) EP3681475B1 (fr)
JP (1) JP2020536972A (fr)
KR (1) KR20200125923A (fr)
CN (1) CN111526869A (fr)
AU (1) AU2018353360B2 (fr)
BR (1) BR112020007569A2 (fr)
CA (1) CA3079303A1 (fr)
CO (1) CO2020005939A2 (fr)
DK (1) DK3681475T3 (fr)
EA (1) EA202090965A1 (fr)
ES (1) ES2858573T3 (fr)
HR (1) HRP20210260T1 (fr)
HU (1) HUE053233T2 (fr)
IL (1) IL273967A (fr)
LT (1) LT3681475T (fr)
MA (1) MA50247B1 (fr)
MX (1) MX2020003834A (fr)
PL (1) PL3681475T3 (fr)
PT (1) PT3681475T (fr)
SG (1) SG11202003384XA (fr)
TW (1) TW201922250A (fr)
WO (1) WO2019076798A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition
CN116211795B (zh) * 2022-12-26 2025-09-26 深圳市贝美药业有限公司 一种比拉斯汀口服液体制剂及其制备方法
WO2025256637A1 (fr) * 2024-06-14 2025-12-18 北京普祺医药科技股份有限公司 Spray nasal d'inhibiteur de tyrosine kinase

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
FR2780901B1 (fr) * 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20060045850A1 (en) 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
CA2613439A1 (fr) 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Conjugues d'hydrazide en tant qu'agents d'imagerie
WO2007047253A2 (fr) 2005-10-11 2007-04-26 Eastman Chemical Company Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole
EP1894559A1 (fr) 2006-09-01 2008-03-05 PARI Pharma GmbH Stabilisation de stéroides destinées à être inhalées
CN101273993A (zh) * 2007-03-27 2008-10-01 北京亚欣保诚医药科技有限公司 糠酸莫米松溶液型液体制剂
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CN101756998A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 采用环糊精包合糠酸莫米松的鼻用药物组合物
CN201373609Y (zh) 2009-03-13 2009-12-30 潘戈 太阳能集热器箱体
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
KR101304341B1 (ko) 2011-09-19 2013-09-11 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
US9629847B2 (en) 2011-11-23 2017-04-25 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
CN103736098A (zh) * 2013-12-27 2014-04-23 于运红 一种含有比拉斯汀及糠酸莫米松的鼻内给药用药物组合物
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (fr) * 2014-12-29 2016-07-06 Faes Farma, S.A. Nouveaux dérivés de benzimidazole en tant qu'agents antihistaminiques
WO2016141219A1 (fr) 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Compositions et formulations à base de strontium contre la douleur, le prurit et l'inflammation
WO2017008265A1 (fr) * 2015-07-15 2017-01-19 Abb Technology Ag Barre conductrice avec partie annulaire pour loger un élément de connexon de test
EP3170816A1 (fr) * 2015-11-20 2017-05-24 Faes Farma, S.A. Compositions sursaturées de composés de benzimidazole

Also Published As

Publication number Publication date
US11642309B2 (en) 2023-05-09
JP2020536972A (ja) 2020-12-17
KR20200125923A (ko) 2020-11-05
MA50247A (fr) 2020-07-22
US20210186869A1 (en) 2021-06-24
DK3681475T3 (da) 2021-02-01
LT3681475T (lt) 2021-02-25
ES2858573T3 (es) 2021-09-30
HUE053233T2 (hu) 2021-06-28
AU2018353360A1 (en) 2020-05-07
AU2018353360B2 (en) 2021-04-01
EP3681475A1 (fr) 2020-07-22
PT3681475T (pt) 2021-03-08
MX2020003834A (es) 2020-08-06
SG11202003384XA (en) 2020-05-28
WO2019076798A1 (fr) 2019-04-25
EA202090965A1 (ru) 2020-07-22
PL3681475T3 (pl) 2021-07-05
CN111526869A (zh) 2020-08-11
BR112020007569A2 (pt) 2020-09-24
CA3079303A1 (fr) 2019-04-25
HRP20210260T1 (hr) 2021-04-02
EP3681475B1 (fr) 2020-12-09
TW201922250A (zh) 2019-06-16
CO2020005939A2 (es) 2020-10-30
IL273967A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
Aapro 5-HT3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis
EP4631944A3 (fr) Rimegepant pour troubles liés au cgrp
MA50247A (fr) Compositions aqueuses comprenant de la bilastine et du mométasone
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA56038B1 (fr) Inhibiteurs à petite molécule de kinase induisant nf-kb
BR112021020694A2 (pt) Composições farmacêuticas de bilastina estáveis e preservadas
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
WO2021074649A3 (fr) Procédés pour favoriser la production de scfa par le microbiote intestinal
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
Kampf et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability
CA3156182A1 (fr) Procedes de traitement d'etats lies au recepteur s1p1
MX2022000297A (es) Formulacion de naltrexona.
EP3686185A4 (fr) Dérivé de fluorène ou sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée au vhc
JP2025531623A (ja) タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法